Elie El Rassy

TL;DR: It seems that PARP inhibitor and biologic agent combinations appear well tolerated and clinically effective in both BRCA-mutated and wild-type cancers, and overlapping myelosuppression observed with PARP inhibitors and chemotherapy combinations requires further investigation with dose escalation studies.

TL;DR: The clinical data of single-agent TKIs and ICIs in mRCC and the rationale for the combination ICIs and TKis based on preclinical and clinical evidence are discussed.

TL;DR: The scientific evidence that has emerged from both experimental and clinical studies in the development of talazoparib is discussed, and future directions will include optimizing combination therapy with chemotherapy, immunotherapies and targeted therapies, and in developing and validating biomarkers for patient selection and stratification, particularly in malignancies with ‘BRCAness’.

TL;DR: The mechanism of action of veliparib is summarized and an overview of its early and ongoing clinical investigations are provided, which show promising results available in preclinical and early clinical settings.

TL;DR: The variations in the incidence-rate of cancer of unknown primary over time and between countries reflect changes in the risk factors for CUP, incidence trends of the primary tumors that potentially contribute to the burden of CUP and change in the diagnostic technologies and practice.